SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+1.73%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$124M
AUM Growth
+$124M
(-22%)
Cap. Flow
-$70.5M
Cap. Flow
% of AUM
-56.93%
Top 10 Holdings %
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
13
Reduced
18
Closed
6
Top Buys
| 1 |
TELA Bio
TELA
|
$3.75M |
| 2 |
Inhibikase Therapeutics
IKT
|
$3.68M |
| 3 |
Inovio Pharmaceuticals
INO
|
$1.92M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$1.91M |
| 5 |
CalciMedica
CALC
|
$1.66M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$34.1M |
| 2 |
ADMA Biologics
ADMA
|
$10.8M |
| 3 |
Kezar Life Sciences
KZR
|
$9.28M |
| 4 |
Galapagos
GLPG
|
$7.66M |
| 5 |
Royalty Pharma
RPRX
|
$6M |
Sector Composition
| 1 | Healthcare | 99.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vir Biotechnology
VIR
$686M
| $1.2M | 0.97% |
+164,106
| New | +$1.2M |
|
27
Milestone Pharmaceuticals
MIST
$156M
| $1.18M | 0.95% |
500,000
-499,790
| -50% | -$1.18M |
|
28
ANI Pharmaceuticals
ANIP
$2.03B
| $1.13M | 0.91% |
+20,400
| New | +$1.13M |
|
29
Heron Therapeutics
HRTX
$207M
| $1.07M | 0.86% |
+700,000
| New | +$1.07M |
|
30
Exagen
XGN
$217M
| $1.03M | 0.83% |
251,049
-283,349
| -53% | -$1.16M |
|
|
TSVT
31
DELISTED
2seventy bio
TSVT
| $882K | 0.71% |
300,000
+200,000
| +200% | +$588K |
|
32
iTeos Therapeutics
ITOS
| $845K | 0.68% |
110,000
+80,000
| +267% | +$614K |
|
33
PMV Pharmaceuticals
PMVP
$74.2M
| $809K | 0.65% |
+535,805
| New | +$809K |
|
|
34
Kezar Life Sciences
KZR
$28.9M
| $739K | 0.6% |
110,000
-1,381,305
| -93% | -$9.28M |
|
35
AYTU BioPharma
AYTU
$21.1M
| $693K | 0.56% |
407,549
-93,409
| -19% | -$159K |
|
36
Adicet Bio
ACET
$59.9M
| $673K | 0.54% |
700,000
+90,554
| +15% | +$87.1K |
|
37
Kiora Pharmaceuticals
KPRX
$9.55M
| $663K | 0.54% |
200,970
-1,430
| -0.7% | -$4.72K |
|
38
Xeris Biopharma Holdings
XERS
$1.26B
| $618K | 0.5% |
+182,317
| New | +$618K |
|
39
Aquestive Therapeutics
AQST
$456M
| $570K | 0.46% |
+160,000
| New | +$570K |
|
40
Aprea Therapeutics
APRE
$9.09M
| $491K | 0.4% |
149,221
+12,047
| +9% | +$39.6K |
|
|
SLRN
41
DELISTED
ACELYRIN
SLRN
| $417K | 0.34% |
+132,870
| New | +$417K |
|
42
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $345K | 0.28% |
+250,000
| New | +$345K |
|
43
PolyPid
PYPD
$53.3M
| $315K | 0.25% |
103,668
-34,836
| -25% | -$106K |
|
44
HilleVax
HLVX
$105M
| $274K | 0.22% |
+132,347
| New | +$274K |
|
45
AN2 Therapeutics
ANTX
$30.1M
| $271K | 0.22% |
+196,732
| New | +$271K |
|
46
Vanda Pharmaceuticals
VNDA
$279M
| $120K | 0.1% |
+25,000
| New | +$120K |
|
|
ELEV
47
DELISTED
Elevation Oncology
ELEV
| $113K | 0.09% |
+200,000
| New | +$113K |
|
|
ABVX
48
Abivax
ABVX
$6.12B
| $110K | 0.09% |
+15,000
| New | +$110K |
|
|
ALLR
49
Allarity Therapeutics
ALLR
$22.5M
| $78.7K | 0.06% |
+67,289
| New | +$78.7K |
|
|
RVNC
50
DELISTED
Revance Therapeutics, Inc.
RVNC
| $70.7K | 0.06% |
23,264
-796,736
| -97% | -$2.42M |
|